LIGHT SCIENCES ONCOLOGY COMPLETES SECOND CLOSING IN $67 MILLION FINANCING FOR LATE STAGE DEVELOPMENT OF LITX

Light Sciences Oncology, Inc., a privately held company focused on the development of Light Infusion Technology (Litx) for the treatment of solid tumors, announced today that it has completed an offering of an additional $32 million of its Series A Preferred Stock. The completion follows by two months the initial closing of $35 million of Series A Preferred and brings the total amount of Series A Preferred to $67 million.
Business Wire